Diphenylether

Diphenylether

SCHEMBL457909

NNC(N)=S.c1ccc(Oc2ccccc2)cc1

nearest known ligand 0.55

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LTA4H P09960 4/20 0.55
TSHR P16473 2/20 0.55
ALDH1A1 P00352 6/20 0.52
HPGD P15428 2/20 0.52
ALOX12 P18054 2/20 0.52
CYP3A4 P08684 1/20 0.52
CYP2D6 P10635 1/20 0.52
CYP2C9 P11712 1/20 0.52
CYP2C19 P33261 1/20 0.52
PARP10 Q53GL7 1/20 0.50
NR1H2 P55055 1/20 0.48
BAX Q07812 1/20 0.48
MAOA P21397 1/20 0.48
HSD17B10 Q99714 2/20 0.46
TP53 P04637 1/20 0.46
TYR P14679 1/20 0.46
TAS2R38 P59533 1/20 0.46
KDM4E B2RXH2 1/20 0.46
HTT P42858 2/20 0.46
MEN1 O00255 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Carbamic Acid Phenyl Ester SCHEMBL28258878 0.79 MEN1 (0.53) TSHRALDH1A1HPGDPARP10HSD17B10
SCHEMBL653550 0.79 ALDH1A1 (0.85) TSHRALDH1A1HPGDALOX12CYP3A4
Diphenylether SCHEMBL3677041 0.79 LTA4H (0.57) LTA4HTSHRALDH1A1HPGDPARP10
Biphenyl SCHEMBL27814668 0.78 ALDH1A1 (0.53) TSHRALDH1A1CYP3A4HSD17B10TP53
Diphenylether SCHEMBL11115509 0.77 LTA4H (0.55) LTA4HTSHRALDH1A1HPGDPARP10
Diphenylether SCHEMBL10597664 0.77 LTA4H (0.80) LTA4HTSHRPARP10NR1H2BAX
Benzene SCHEMBL27713962 0.77 ALDH1A1 (0.77) TSHRALDH1A1HPGDMAOAHSD17B10
Anthracene SCHEMBL28541427 0.76 ALDH1A1 (0.55) TSHRALDH1A1ALOX12CYP3A4CYP2D6
Phenol SCHEMBL28148833 0.76 CA1 (0.55) TSHRALDH1A1MAOAHSD17B10TP53
SCHEMBL2880841 0.76 PARP10 (0.64) LTA4HTSHRALDH1A1PARP10NR1H2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2240175-B1 COMPOUNDS WITH MDR1-INVERSE ACTIVITY US GOV HEALTH & HUMAN SERV (US) 2013-01-02 EP disclosed
WO-2012033601-A1 THIOSEMICARBAZONES WITH MDR1 - INVERSE ACTIVITY THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES (US) 2012-03-15 WO disclosed
US-20100316655-A1 COMPOUNDS WITH MDR1-INVERSE ACTIVITY INSTITUTE OF ENZYMOLOGY, BIOLOGICAL RESEARCH CENTER, HUNGARIAN ACADEMY OF SCIENCES (HU) 2010-12-16 US disclosed
EP-2240175-A2 COMPOUNDS WITH MDR1-INVERSE ACTIVITY The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services (US) 2010-10-20 EP disclosed
WO-2009102433-A2 COMPOUNDS WITH MDR1-INVERSE ACTIVITY THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2009-08-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100316655-A1 COMPOUNDS WITH MDR1-INVERSE ACTIVITY ABCC1, ABCB1, ABCC2 LTA4H 3192/4885TSHR 4378/4885ALDH1A1 1607/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.